| Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 10426875 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Early patency of the infarct-related vessel improves in-hospital and long-term survival. Mechanical reopening is as effective as or superior to pharmacological therapy in the treatment of acute myocardial infarction. However, in patients treated with primary percutaneous transluminal coronary angioplasty, recurrent ischemia occurs in 10% to 15% before hospital discharge, and angiographic restenosis occurs in 30% to 50% of infarct-related vessel within 6 months. Primary stenting in acute myocardial infarction has been found to be safe and feasible and reduces early and late events. In particular, restenosis rate has been found to be lowered by stent implantation. Use of glycoprotein IIb/IIIa receptor inhibitors alone has resulted in infarct-related vessel patency rates approximately the same as with the use of thrombolytic therapy. Furthermore, glycoprotein IIb/IIIa receptor blockers reduce the occurrence of acute complications during percutaneous transluminal coronary angioplasty. Preliminary results of some ongoing trials showed that the combined therapeutic approach (ie, primary stenting plus glycoprotein IIb/IIIa inhibitors) in patients with acute myocardial infarction reduces both early and late complications of percutaneous transluminal coronary angioplasty. This finding supports the concept that optimal mechanical resolution of the plaque and the inhibition of platelet aggregation are the key of the treatment of the infarct-related vessel. |
| | |
Authors:
|
A Colombo; C Briguori |
Related Documents
:
|
1732685 - Outcome of noncardiac operations in patients with severe coronary artery disease succes... 9046535 - Measurement of angioplasty lumen volume and wall compliance: a laboratory study. 7978505 - Long-term follow-up after peripheral and coronary angioplasty in patients undergoing bo... 12841485 - The current practice of percutaneous transluminal coronary angioplasty (ptca) and stent... 3066485 - The restrictive cardiomyopathies. 22395345 - Tissue-engineered heart valve: future of cardiac surgery. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American heart journal Volume: 138 ISSN: 0002-8703 ISO Abbreviation: Am. Heart J. Publication Date: 1999 Aug |
Date Detail:
|
Created Date: 1999-08-30 Completed Date: 1999-08-30 Revised Date: 2006-02-27 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: S153-7 Citation Subset: AIM; IM |
Affiliation:
|
EMO Centro Cuore Columbus, San Raffaele Hospital, Milan, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary Coronary Angiography Coronary Vessels / pathology Feasibility Studies Humans Myocardial Infarction / drug therapy, therapy* Myocardial Ischemia / etiology Platelet Aggregation Inhibitors / therapeutic use* Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors* Platelet Glycoprotein GPIb-IX Complex* Platelet Membrane Glycoproteins* Receptors, Antigen, B-Cell / antagonists & inhibitors* Receptors, Cell Surface / antagonists & inhibitors* Recurrence Safety Stents* Survival Rate Thrombolytic Therapy Vascular Patency |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Platelet Glycoprotein GPIb-IX Complex; 0/Platelet Membrane Glycoproteins; 0/Receptors, Antigen, B-Cell; 0/Receptors, Cell Surface; 0/glycoprotein receptor GPIb-IX |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Current role of stenting in acute myocardial infarction.
Next Document: Do new devices add to the results of PTCA in acute myocardial infarction?